Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993371 | 0.89 | CETP (0.74) | CETP | |
| SCHEMBL7154158 | 0.87 | CETP (0.61) | CETP | |
| SCHEMBL992738 | 0.86 | CETP (0.64) | CETP | |
| SCHEMBL6477347 | 0.85 | CETP (0.49) | CETP | |
| SCHEMBL7908786 | 0.84 | CETP (0.52) | CETP | |
| SCHEMBL7154159 | 0.83 | CETP (0.51) | CETP | |
| SCHEMBL6475752 | 0.82 | CETP (0.47) | CETP | |
| SCHEMBL992806 | 0.81 | CETP (0.58) | CETP | |
| SCHEMBL6475766 | 0.80 | CETP (0.62) | CETP | |
| SCHEMBL662851 | 0.80 | CETP (0.51) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897317-B2 | 4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | BAYER AKTIENGESELLSCHAFT (DE) | 2005-05-24 | — | — | US | disclosed |
| US-20030232990-A1 | 4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | BAYER AKTIENGESELLSCHAFT | 2003-12-18 | — | — | US | disclosed |
| US-6562976-B2 | Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| US-20020165252-A1 | 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | BAYER AKTIENGESELLSCHAFT | 2002-11-07 | — | — | US | disclosed |
| US-20020042515-A1 | Tetrahydroquinolines | SCHMIDT GUNTER (DE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042515-A1 | Tetrahydroquinolines | HMGCR, DHCR7, LIPA | CETP 7/4885 |
| US-20020165252-A1 | 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | CETP, LCAT, ACAT2 | CETP 1/4885 |
| US-20030232990-A1 | 4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | CETP, LCAT, ACAT2 | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.